drugset / Trial / NCT01975220
Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combination (FDC) tablets containing empagliflozin \& metformin and the single tablets of empagliflozin and metformin when administered singularly.
Timeline
- Start
- 2013-10
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 12.5 mg | — |
| Subject | Empagliflozin | Small molecule | 25 mg | — |
| Subject | Metformin | Small molecule | 750 mg | — |
| Subject | Metformin | Small molecule | 1000 mg | — |
Indications
No indication recorded.